Successful cryopreservation of purified autologous CD34 cells: influence of freezing parameters on cell recovery and engraftment
|
|
- Bryce Horn
- 5 years ago
- Views:
Transcription
1 Bone Marrow Transplantation, (1998) 22, Stockton Press All rights reserved /98 $ Successful cryopreservation of purified autologous CD34 cells: influence of freezing parameters on cell recovery and engraftment F Beaujean 1, J-H Bourhis 2, Ch Bayle 2, H Jouault 3, M Divine 3, C Rieux 3, M Janvier 4, Ch Le Forestier 1 and JL Pico 2 1 Laboratoire de Thérapie Cellulaire, Centre de Transfusion Sud Est Francilien, Hôpital Henri Mondor, Créteil; 2 Département d Hématologie Clinique et Biologique, Institut Gustave Roussy, Villejuif; 3 Département d Hématologie Clinique et Biologique, Hôpital Henri Mondor, Créteil; and 4 Département d Hématologie Clinique, Centre René Huguenin, Saint-Cloud, France Summary: Conventional hematopoietic stem cell cryopreservation methods use a DMSO concentration of 10%. However, cells manipulated ex vivo may require more refined freezing protocols adapted to the specific cell suspension. In this retrospective study, we evaluated the results obtained with CD34 cells purified from peripheral blood of 39 patients on the CEPRATE SC System and frozen in 7.5% DMSO with a view to transplantation. The post-freezing recovery of progenitor cells was % for CD34 cells, % for CFU-GM, and for BFU-E. Neither the purity of the suspension nor the nucleated cell density during freezing was predictive of cell recovery. No difference was observed between cells stored in vials and bags. Thirty-seven patients transplanted with the concentrated CD34 fraction received CD34 cells/kg and CFU-GM/kg. The median time to granulocyte ( /l) and platelet ( /l) engraftment was 11 and 13 days, respectively. Only cell density and the infused number of CD34 cells and CFU-GM were significantly related to hematological recovery. Our data suggest that purified CD34 cells can be successfully cryopreserved in 7.5% DMSO and may represent a first step in establishing freezing parameters for selected CD34 cells. Keywords: purified CD34 cells; cryopreservation; hematopoietic recovery Successful stem cell-based therapies, including autologous hematopoietic rescue, generally require an efficient method of long-term preservation. Current cryobiology techniques were defined many years ago and generally involve the use of dimethylsulfoxide (DMSO) as cryoprotectant, a slow cooling rate, and storage below 120 C. 1,2 Available methods can be used successfully to reconstitute normal hematopoiesis in heavily myelosuppressed patients. How- Correspondence: F Beaujean, Laboratoire de Thérapie Cellulaire, Etablissement de Transfusion Sanguine du Sud-Francilien, Hôpital Henri Mondor, 51, Avenue du Maréchal de Lattre de Tassigny, Créteil, France Received 12 May 1998; accepted 21 July 1998 ever, hematopoietic stem cell processing for transplantation has changed considerably in recent years. Hematopoietic cells can now be obtained from a variety of sources and ex vivo manipulation of hematopoietic grafts, by means of tumor purging, CD34 enrichment or T cell depletion has become relatively common. These techniques have introduced novel cellular products into clinical trials and routine practice. 3 There have been few studies aimed at determining if conventional freezing protocols are appropriate for such manipulated cells and ensure sufficient numbers of viable cells for reliable engraftment. In autologous transplantation, positive selection of CD34 cells reduces the amount of contaminating tumor cells in apheresis products without impairing hematopoietic recovery. 4 Isolation of CD34 cells results in a 2-log reduction in the total nucleated cell count, especially of mature blood elements, resulting in a highly purified population at a low cell density, thereby reducing the volume of the graft. 5 In this retrospective study, peripheral blood stem cells (PBSC) were positively selected by immunoadsorption using the CEPR- ATE SC Stem Cell Concentration System (CellPro, Bothell, WA, USA) and then frozen with a view to transplantation. In keeping with the company s guidelines, purified CD34 cells were cryopreserved with 7.5% DMSO and stored, depending on the clinical protocol, in either vials or bags. These conditions differed from our conventional protocol established for unmanipulated stem cell grafts (cryoprotectant concentration of 10% and a bag storage system). In order to evaluate cell cryosurvival in these new conditions and to determine the specific effect of a low cell density during freezing, we studied the post-freezing results of CD34 cells isolated from 39 patients, with regard to cell viability and engraftment kinetics after treatment with severely myelosuppressive regimens. Materials and methods Patient populations and mobilization procedures Between April 1993 and February 1997, 39 consecutive patients from three institutions were eligible for PBSC collection and selection. The diagnoses comprised multiple myeloma (16 patients), non-hodgkin s lymphoma (16 patients), breast cancer (6 patients), and chronic lymphoid leukemia (1 patient). The age range was 37 to 62 years
2 1092 (median 51). The study protocol was approved by the institutional review board and all the patients gave their written informed consent. PBSC were collected after high-dose chemotherapy followed by G-CSF (filgrastim; Amgen, Thousand Oaks, CA, USA). The timing of PBSC collection was based on an absolute white blood cell count exceeding /l. All the patients underwent daily leukapheresis sessions (12 l of blood each) on a Cobe Spectra cell separator (Cobe BCT, Lakewood, CO, USA). Anticoagulation was obtained with acid-citrate-dextrose (ACD.A; Baxter, Maurepas, France) at a ratio of 1 ml to 10 ml of blood. PBSC processing Two leukapheresis products were processed to positively select CD34 cells. The first apheresis product was stored overnight at 4 C and pooled with the second before further processing. Forty procedures were performed on 39 patients, one patient having two column separations because the threshold dose of CD34 cells ( /kg) was not achieved after the first selection. CD34 immunoselection was performed according to the instructions of the CEPRATE SC Stem Cell Concentration System manufacturer. Briefly, pooled PBSC were washed and resuspended in 150 ml of PBS (phosphate-buffered saline without Ca or Mg (CellPro)) containing 0.1% human serum albumin (HSA) (Laboratoire Français du Fractionnement et des Biotechnologies, Les Ulis, France). Cells were incubated for 25 min at room temperature with 20 g/ml of the biotinylated anti-cd34 monoclonal antibody The treated cells were washed with PBS to remove unbound antibody and processed through the avidin-coated column of the CEPRATE SC device. After washing, CD34 cells were recovered by mechanical agitation, resuspended in 80 ml of PBS containing 5 ml of 20% HSA and concentrated. Cryopreservation protocol Cryopreservation solution, consisting of 15% dimethyl sulfoxide (DMSO) in 8% HSA, was added to the cell products at an equal volume, to achieve a final concentration of 7.5% DMSO. The cryoprotectant solution was chilled to 4 C before use. Two freezing containers were used during the study. In 22 cases, cells from patients enrolled in specific protocols were transferred into cryovials (4 ml each). In the other 18 procedures, cells (40 ml) were placed in a minimum of two freezing bags (Hemofreeze bag DF 200; Gambro, Heckingen, Germany). Because of the different storage volumes, cell density in the bags was approximately half that in the vials. The cells, in vials or bags, were frozen using appropriate programs with a controlled cooling rate of 1 C/min to 50 C and then 5 C/min to 80 C, using a Planer Kryo 10 rate controller and chamber (Planer Biomed, Sunbury, UK). The vials were stored in the vapor phase of liquid nitrogen and the bags in the liquid phase. Before reinfusion the cells were rapidly thawed in a water bath at 40 C. Cells in vials were diluted with five volumes of PBS in the first nine procedures, and with 4% HSA in the remaining 13 procedures. An equal volume of 4% HSA was added to the cell suspension in bags. The cells were then promptly re-infused over 5 10 min. Quality control Samples were taken before and after cryopreservation. Quality control procedures for all the products included total nucleated cell counts, viability, CD34 cell counts and measurement of granulocyte macrophage colony-forming units (CFU-GM) and burst-forming unit-erythroid (BFU-E) content. Nucleated cell counts were done manually with a Malassez chamber (Ateliers Cloup, Champigny sur Marne, France). Trypan blue dye exclusion was used to estimate the percentage viability of nucleated cells. All results are expressed in terms of viable cells. Flow cytometry was used to estimate the number of CD34 cells with a phycoerythrin (PE) or fluorescein isothiocyanate (FITC) conjugated anti-cd34 monoclonal antibody HPCA 2 (Becton Dickinson, San Jose, CA, USA). For each sample, cells were incubated with 20 l of HPCA 2-PE or FITC or an irrelevant isotype control monoclonal antibody at 4 C for 30 min. After washing, samples were analyzed in a FacScan (Becton Dickinson) or Epics-Profile II (Coulter, Miami, FL, USA) flow cytometer and events were acquired. The resulting percentage of CD34 cells was multiplied by the number of nucleated cells to obtain the total number. Granulocyte macrophage colony-forming units (CFU- GM) and burst-forming units-erythroid (BFU-E) were simultaneously evaluated in ready-to-use culture medium (Methocult H4431; Stem Cell Technologies, Vancouver, Canada) consisting of IMDM (Iscove s modified Dulbecco s medium), 0.9% methyl cellulose, 30% FCS, 1% bovine serum albumin, 10 4 m 2-mercaptoethanol, 2 mm l-glutamine, 10% agar leukocyte conditioned medium and 3 U/ml human recombinant erythropoietin. Cells were plated in triplicate in 35-mm plastic culture dishes at densities of /ml and /ml. The dishes were maintained at 37 C in 100% humidified air with 5% CO 2. Colonies containing more than 50 cells were scored after 14 days of culture. CD34 cell infusion and hematopoietic recovery Thirty-seven of the 39 patients were transplanted with autologous selected CD34 cells alone. Conditioning regimens consisted of chemotherapy with (n = 31) or without (n = 6) total body irradiation (TBI). All the patients received G- CSF at a dose of 5 g/kg, starting 1 day after the infusion of selected cells and continuing until the neutrophil count was at least 10 9 /l on 3 consecutive days. The time required for engraftment was defined as the number of days required for patients to achieve neutrophils/l and platelets/l. Statistical analysis The results are expressed as means and standard deviations (s.d.) unless otherwise indicated. Post-cryopreservation recovery of progenitor cells (CD34 cells, CFU-GM and BFU-E) was obtained by dividing the absolute number of progenitor cells after thawing by the corresponding value before freezing ( 100). Correlations between cell density, recovery of myeloid (CFU-GM), erythroid (BFU-E) and
3 CD34 cells, and the time to engraftment were studied by using the non-parametric Spearman test. Two-way factorial analysis of variance (ANOVA) was used to compare the results obtained with the two types of freezing container. Significance was set at P Results In vitro studies Forty positive selection procedures were performed on 39 patients. All selected products were frozen, thawed and evaluable for the study. After CD34 cell selection, the mean ( s.d.) number of viable cells was in a final mean volume of ml ( 30.34). The purity of CD34 cells ranged from 33.9% to 97%, with a mean value of 84.65% Purity was above 80% in 30 of the 40 samples. After the addition of cryoprotectant, the nucleated cell density ranged from to /ml, with an average of /ml. After thawing and dilution, the recovery of nucleated cells and CD34 cells was respectively 88.62% (range: ) and 89.44% (range: ). Thirty-seven of the 40 samples had better than 60% of CD34 cell recovery. The mean purity and viability of the thawed suspensions were respectively 84.65% and 81.73% The progenitor recovery rates were 59.13% for CFU-GM and 53.49% for BFU-E. CD34 cell recovery correlated well with the recovery of nucleated cells (r = 0.94, P ), CFU- GM (r = 0.53, P = ) (Figure 1) and BFU-E (r = 0.45, P = ). Initial CD34 cell purity was not predictive of any of these parameters (r = 0.09, P = 0.54). We also explored the predictive value of nucleated cell density on progenitor cell survival. No correlation was found between % CFU-GM recovery % CD34+ cell recovery Figure 1 Correlation between CD34 cell and CFU-GM recoveries after cryopreservation (r = 0.53, P = ). this parameter and the recovery of CD34 cells (r = 0.23), CFU-GM (r = 0.22) or BFU-E (r = 0.22). The effect of the type of freezing container on cell and progenitor recovery was then explored (Table 1). The mean cell density in vials was nucleated cells/ml (range ), whereas cell density in the bags was nucleated cells/ml (range: ). Although cell density was significantly different (P = 0.02), the results obtained with the two types of container were of the same order. Cells frozen in vials yielded post-thaw nucleated cell and CD34 cell recoveries of % and %, respectively. Cells frozen in bags yielded slightly but not significantly better recovery ( % for nucleated cells and % for CD34 cells). CFU-GM and BFU-E activities after cryopreservation were similar regardless of whether cells were stored in vials or bags. Although the number of samples was limited, the effects of PBS and HSA as post-thaw solutions were compared (Table 2). No significant difference was observed (P = 0.3), although there was a trend towards better CD34 cell yields after dilution with 4% HSA. Clinical data Thirty-seven patients were reinfused with a median of 4.46 ( ) 10 6 /kg CD34 cells and ( ) 10 4 /kg CFU-GM. No side-effects occurred during infusion of selected CD34 cells. However, one patient became febrile within 24 h of transfusion, and blood culture yielded Pseudomonas rickettii. The same organism was isolated from the post-thaw sample of the graft (frozen in a cryovial). The infection resolved on appropriate antibiotic therapy. All patients showed successful neutrophil engraftment, taking a median of 11 days (range 6 to 20) to recover a count of /l. Thirty-five patients achieved a platelet count above /l a median of 13 days after transplantation (range 9 to 125 days). Thirty-one of these patients showed platelet engraftment within 21 days. Two patients did not achieve platelet recovery, because of relapses on days 85 and 90 (they had been reinfused with /kg and /kg CD34 cells). The longest case of thrombocytopenia (125 days) was observed in a patient who developed hepatic veno-occlusive disease and who had received the lowest dose of CD34 cells ( /kg). The time to neutrophil and platelet engraftment correlated negatively with the CD34 cell number infused (r = 0.58, P = and r = 0.38, P = , respectively). We also found a negative correlation (r = 0.40, P = 0.013) between the CFU-GM dose and the speed of neutrophil recovery. The number of BFU-E was not predictive of engraftment. The predictive value of cell density during cryopreservation on engraftment kinetics was also studied. Lower cell densities were associated with longer times to achieve granulocytes/l (r = 0.45, P = ) and to achieve platelet recovery (r = 0.36, P = 0.03). No differences in hematological recovery were observed between patients receiving grafts frozen and stored in vials or in bags (Table 3). 1093
4 1094 Table 1 Effects of the freezing container on cell recovery Vials (n = 22) Bags (n = 18) Cell density ( 10 6 /ml) P 0.05 Volume frozen (ml) Recovery post-freezing (%) Nucleated cells NS CD34 cells NS CFU-GM NS BFU-E NS Values are expressed as mean s.d. NS = not significant. Table 2 Cell recovery through the post-thaw dilution step Dilution in PBS Dilution in HSA (n = 9) (n = 13) Recovery of CD34 cells (%) NS Recovery of CFU-GM (%) NS Recovery of BFU-E (%) NS Values are expressed as mean s.d. NS = not significant. Discussion There is little published information on the best storage conditions for CD34 cell products. This study provides evidence that autologous CD34 cell concentrates isolated with the CellPro device can be efficiently cryopreserved with a final DMSO concentration of 7.5%. This concentration was defined as optimal in preliminary experiments in which the CD34 cell yield post-freezing exceeded 75%. 6 Our data confirm these results and indicate that over 89% of CD34 cells can be recovered. Moreover, cell viability and CD34 cell and clonogenic progenitor (CFU-GM, BFU-E) recoveries were similar to those obtained with unmanipulated hematopoietic products cryopreserved with 10% DMSO. 7,8 These cryopreserved CD34 cells rapidly reconstituted hematopoiesis in our study, even after myeloablative regimens such as total body irradiation. All patients engrafted, and the rates of neutrophil and platelet recovery were similar to those in other published reports with purified CD34 cells. 9 In these studies the methods used to preserve CD34 cells were heterogeneous. The final DMSO concentration varied from 7.5% 10,11 to 10% Hematopoietic reconstitution occurred as rapidly in our patients as in those whose CD34 cells were cryopreserved in 10% DMSO. A DMSO concentration of 10% has been established as optimal for the preservation of hematopoietic stem cells Lower concentrations have mainly been used when DMSO is combined with the extracellular cryoprotectant hydroxyethyl starch. 18 The use of hematopoietic grafts cryopreserved with 10% DMSO is often associated with specific side-effects apparently related to cell lysis debris and the volume of cryoprotectant. 19 Therefore, the use of cryoprotectant solutions containing lower proportions of DMSO is desirable. It was recently reported that blood hematopoietic cells could be cryopreserved with 5% DMSO as the sole cryoprotectant. 20,21 Other teams recommended a concentration of 7.5% for optimal recovery of hematopoietic stem cells in umbilical cord blood depleted of red cells. 22 In our study 7.5% DMSO also preserved efficiently purified CD34 cells. Regarding the clonogenic potential of CD34 cells, a good correlation between CD34 cell content and clonogenic activities was observed. However, CFU-GM and BFU-E cryosurvival (respectively 59.1% and 53.5%) was lower than that of CD34 cells. With the same cryopreservation parameters, Gorin et al 23 reported post-freezing CFU-GM and BFU-E recovery of more than 70% with purified CD34 bone mar- Table 3 Impact of the freezing container on time to engraftment Storage in vials Storage in bags (n = 19) n = 18 CD34 cells 10 6 /kg infused NS ( ) ( ) CFU-GM 10 5 /kg infused NS ( ) ( ) Days post-transplant to: Neutrophils /l NS (7 20) (6 16) Platelets /l NS (9 125) (9 41) The values are given as the mean s.d. with the range in parentheses. NS = not significant.
5 row cells. This disparity may in part be explained by differing sources of selected cells and/or stimulating factors. Our culture conditions were more specific for mature myeloid and erythroid progenitors and were suboptimal. Other investigations are needed to determine the reasons for the defective proliferative potential of CD34 cells, such as an intrinsic defect with increased sensitivity to cryoinjury, or inappropriate culture conditions. Freezing and storage conditions, ie cell density, the type of container, and the post-thaw diluent do not appear to influence the quality of the process. There have been some investigations concerning the effect of high cell density during cryopreservation. 9,24 Few data are available on the very low cell densities used in this study (range /ml to /ml). In previous murine studies, Dicke et al 25 found a significant deterioration of progenitor cell survival when marrow cells were frozen at densities of /ml. In this study, the lower concentrations were obtained with freezing bags, as the products were routinely split between two bags for freezing. We found no detrimental effect of relatively low cell densities on the recovery of CD34 cells or hematopoietic cells. Our data show the feasibility of using vials or bags for freezing cells. Similar data have previously been described. 26,27 However, in routine laboratory practice, bags are more convenient for handling and most manipulations can be performed using closed systems. The only graft contamination we documented in this study concerned cells frozen and stored in vials. Univariate analysis of our results showed that the cell density used for freezing, the CD34 cell number, and the CFU-GM content infused influenced the time required to recover peripheral blood cells. Cell density did not correlate with the total CD34 cell number recovered before freezing and was not therefore related to particularly poor grafts. Thus the mechanism of its adverse effect on engraftment are difficult to explain. This must be confirmed and analyzed in a larger number of procedures. Concerning the relationship between the number of cells infused and the speed of engraftment, our results are consistent with those of other clinical reports. In summary, hematopoietic cell storage conditions must be adapted as new cell processing modalities are developed. This routine study of purified CD34 cell cryopreservation efficiency may represent a first step towards the establishment of freezing parameters for selected CD34 cells. Acknowledgements The authors wish to express their gratitude to Claude Santiano for careful typing of the manuscript and David Young for editorial assistance. This work was supported in part by a grant from PHRC AP-HP (1994). References 1 Sputtek A, Körber Ch. Cryopreservation of red blood cells, platelets, lymphocytes, and stem cells. In: Fuller BJ, Grout BWW (eds). Clinical Applications of Cryobiology. CRC Press: Boca Raton, 1991, pp Rowley D. Hematopoietic stem cell cryopreservation: a review of current techniques. J Hematother 1992; 1: Turner ML, McClelland DBL, Franklin IM. Haemopoietic progenitor cell harvesting, processing and storage: global regulation to ensure the quality of products for patients. Br J Haematol 1997; 99: Lopez M, Lemoine FM, Firat H et al. Bone marrow vs peripheral blood progenitor cells CD34 selection in patients with non-hodgkin s lymphomas: different levels of tumor cell reduction. Implications for autografting. Blood 1997; 90: Berenson RJ, Bensinger WI, Hill RS et al. Engraftment after infusion of CD34 marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: Thompson P, Berenson RJ, Heimfeld S. Optimal cryopreservation of purified CD34 cells for therapeutic and research applications. Blood 1992; 80 (Suppl. 1): 536a. 7 Rowley SD, Bensinger WI, Gooley T et al. Effect of cell concentration on bone marrow and peripheral blood stem cell cryopreservation. Blood 1994; 83: Humpe A, Riggert J, Vehmeyer K et al. Comparison of CD34 cell numbers and colony growth before and after cryopreservation of peripheral blood progenitor and stem cell harvests: influence of prior chemotherapy. Transfusion 1997; 37: Lemoli RM, Fortuna A, Motta MR et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34 cells to remove circulating tumor cells. Blood 1996; 87: Brugger W, Henschler R, Heimfeld S et al. Positively selected autologous blood CD34 cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin and epirubicin. Blood 1994; 84: Mahe B, Milpied N, Hermouet S et al. G-CSF alone mobilizes sufficient peripheral blood CD34 cells for positive selection in newly diagnosed patients with myeloma and lymphoma. Br J Haematol 1996; 92: Schiller G, Vescio R, Freytes C et al. Transplantation of CD34 peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86: Nachbaur D, Fink FM, Nussbaumer W et al. CD34 -selected autologous peripheral blood stem cell transplantation (PBSCT) in patients with poor-risk hematological malignancies and solid tumors. A single-centre experience. Bone Marrow Transplant 1997; 20: Schiller G, Vescio R, Freytes C et al. Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma. Bone Marrow Transplant 1998; 21: Ragab AH, Gilkerson E, Myers M. Factors in the cryopreservation of bone marrow cells from children with acute lymphocytic leukemia. Cryobiology 1977; 14: Wells JR, Sullivan A, Cline MJ. A technique for the separation and cryopreservation of myeloid stem cells from human bone marrow. Cryobiology 1979; 16: Ma DDF, Johnson LA, Chan PM et al. Factors influencing myeloid stem cell (CFU-C) survival after cryopreservation of human marrow and chronic granulocytic leukemia cells. Cryobiology 1982; 19: Stiff PJ, Koester AR, Weidner MK et al. Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethysulfoxide and hydroxyethyl starch without controlled-rate freezing. Blood 1987; 70: Davis JM, Rowley SD, Braine HG et al. Clinical toxicity of 1095
6 1096 cryopreserved bone marrow graft infusion. Blood 1990; 75: Richter E, Rath E, Pawlow I et al. 5% vs 10% dimethylsulfoxide for cryopreservation of bone marrow and peripheral stem cells. Bone Marrow Transplant 1993; 12: Galmés A, Besalduch J, Bargay J et al. Cryopreservation of hematopoietic progenitor cells with 5-percent dimethyl sulfoxide at 80 C without rate-controlled freezing. Transfusion 1996; 36: Donaldson C, Armitage WJ, Denning-Kendall PA et al. Optimal cryopreservation of human umbilical cord blood. Bone Marrow Transplant 1996; 8: Gorin NC, Lopez M, Laporte JP et al. Preparation and successful engraftment of purified CD34 bone marrow progenitor cells in patients with non-hodgkin s lymphoma. Blood 1995; 6: Keung YK, Cobos E, Morgan D et al. High cellular concentration of peripheral blood progenitor cells during cryopreservation adversely affects CFU-GM but not hematopoietic recovery. J Hematother 1996; 5: Dicke KA, Vellekoop L, Spitzer et al. The role of autologous bone marrow transplantation in neoplasia. In: Okunewick JP, Meredith RE (eds). Graft-versus-Leukemia in Man and Animal Models. CRC Press: Boca Raton, 1981, pp Heal JM, Brightman A. Cryopreservation of hematopoietic progenitor cells collected by hemapheresis. Transfusion 1987; 27: Valeri CR, Pivacek LE. Effects of the temperature, the duration of frozen storage, and the freezing container on in vitro measurements in human peripheral blood mononuclear cells. Transfusion 1996; 36:
ORIGINAL ARTICLE Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device a local experience
Malaysian J Pathol 2008; 30(1) : 31 36 ORIGINAL ARTICLE Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device a local experience CF Leong FRCPA, Habsah
Dr.PSRK.Sastry MD, ECMO
Peripheral blood stem cell transplantation (Haematopoietic stem cell transplantation) Dr.PSRK.Sastry MD, ECMO Consultant, Medical Oncology Kokilaben Dhirubhai Ambani Hospital Normal hematopoiesis Historical
It has been widely accepted that cryopreservation
Haematologica 1998; 83:1001-1005 original paper Controlled- versus uncontrolled- cryopreservation of peripheral blood progenitor cells: a prospective multicenter study JAIME PEREZ-OTEYZA, * RAFAEL BORNSTEIN,
Peripheral blood stem cells Number of viable CD34 + cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation
(22) 29, 967 972 22 Nature Publishing Group All rights reserved 268 3369/2 $25. www.nature.com/bmt Peripheral blood stem cells Number of viable CD34 + cells reinfused predicts engraftment in autologous
Autologous peripheral blood stem cells (PBSC)
998; 83-6 9-3-25 9:27 Pagina 489 Haematologica 998; 83:489-495 original paper C D 3 4 + cell dose and CD33 subsets: collection and engraftment kinetics in autologous peripheral blood stem cells tra n s
Carlos Bachier, Josh Potter, Grant Potter, Rominna Sugay, Paul Shaughnessy, Kawah Chan, Veronica Jude, Renee Madden, Charles F.
High White Blood Cell Concentration in the Peripheral Blood Stem Cell Product Can Induce Seizures during Infusion of Autologous Peripheral Blood Stem Cells Carlos Bachier, Josh Potter, Grant Potter, Rominna
Evaluation of clinical scale CD34 cell purification: experience of 71 immunoaffinity column procedures
Bone Marrow Transplantation, (1997) 20, 157 162 1997 Stockton Press All rights reserved 0268 3369/97 $12.00 Evaluation of clinical scale CD34 cell purification: experience of 71 immunoaffinity column procedures
Department of Pharmacy, Georgia Health Sciences University, Augusta, GA, USA 3
Oncology Volume 2012, Article ID 931071, 5 pages doi:10.1155/2012/931071 Research Article Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based
Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split dose escalating study
(2) 25, 371 376 2 Macmillan Publishers Ltd All rights reserved 268 3369/ $15. www.nature.com/bmt Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split
E Aurlien, H Holte, A Pharo, S Kvaløy, E Jakobsen, EB Smeland and G Kvalheim. Summary:
Bone Marrow Transplantation, (1998) 21, 873 878 1998 Stockton Press All rights reserved 268 3369/98 $12. http://www.stockton-press.co.uk/bmt Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide
Immature Reticulocyte Fraction in Guiding Stem Cell Harvest in Autologous Peripheral Blood Stem Cell Transplant
Malaysian Journal Immature of Medicine Reticulocyte and Health Fraction Sciences in (ISSN Guiding 1675-8544); Stem Cell Harvest Vol. 10 (1) in Autologous Jan 2014: 1-6 Peripheral Blood Stem Cell Transplant
Introduction STEM CELLS 1994;12:
Growth Factor Stimulation of Cryopreserved CD34 Bone Marrow Cells Intended for Transplant: An In Vitro Study to Determine Optimal Timing of Exposure to Early Acting Cytokines Mariusz Z. Ratajczak, Janina
ISCT Workshop #7 Perspectives in Cell Selection Immunomagnetic Selection
ISCT Workshop #7 Perspectives in Cell Selection Immunomagnetic Selection Carolyn A. Keever-Taylor, PhD Medical College of Wisconsin June 7, 2012 History of Available Devices CellPro CEPRATE Avidin/Biotin
Analysis of the Viability of Umbilical Cord blood Stem Cells. Sachdeva N
Jsrm/Vol5No.11, 2009 Original Article Analysis of the of Umbilical Cord blood Stem Cells Sachdeva N Dr. Neelam Sachdeva Reader, Department of Zoology, Gargi College, University of Delhi, Siri Fort Road,
Hematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte-macrophage colonystimulating factor (G-CSF).
Hematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte colony-stimulating factor(g-csf). Granulocyte-macrophage colonystimulating factor (G-CSF). Interleukin-11
Feasibility of hyperthermia as a purging modality in autologous bone marrow transplantation Wierenga, Pieter Klaas
University of Groningen Feasibility of hyperthermia as a purging modality in autologous bone marrow transplantation Wierenga, Pieter Klaas IMPORTANT NOTE: You are advised to consult the publisher's version
CD34+ Cells: A Comparison of Stem and Progenitor Cells in Cord Blood, Peripheral Blood, and the Bone Marrow
White Paper September 2016 CD34+ Cells: A Comparison of Stem and Progenitor Cells in Cord Blood, Peripheral Blood, and the Bone Marrow Lily C. Trajman, PhD Introduction: Hematopoietic Stem Cells (HSCs)
& 2007 Nature Publishing Group All rights reserved /07 $
(7), 437 441 & 7 Nature Publishing Group All rights reserved 268-3369/7 $. www.nature.com/bmt ORIGINAL ARTICLE Patients mobilizing large numbers of CD34 þ cells ( super mobilizers ) have improved survival
Sterility Testing of Peripheral Blood Stem cell (PBSC) harvests in a Tertiary Oncology Setup
Sterility Testing of Peripheral Blood Stem cell (PBSC) harvests in a Tertiary Oncology Setup Bankar S 1, Tirlotkar A 1, Ojha S 1, Bhat V 2,Kannan S 3, Rajadhyaksha S 1 1. Department of Transfusion Medicine,
Original article. Introduction
Original article Annals of Oncology 14: 475 480, 2003 DOI: 10.1093/annonc/mdg107 CD34+-selected versus unmanipulated autologous stem cell transplantation in multiple myeloma: impact on dendritic and immune
THE INFLUENCE OF SODIUM FLUORIDE ON THE CLONOGENECITY OF HUMAN HEMATOPOIETIC PROGENITOR CELLS: PRELIMINARY REPORT
168 Fluoride Vol. 33 No. 4 168-173 2 Research Report THE INFLUENCE OF SODIUM FLUORIDE ON THE CLONOGENECITY OF HUMAN HEMATOPOIETIC PROGENITOR CELLS: PRELIMINARY REPORT Boguslaw Machaliński, a Maria Zejmo,
Graft source and Stem cell collection SULADA PUKIAT, MD
+ Graft source and Stem cell collection SULADA PUKIAT, MD + Hematopoietic stem cells Hematopoietic stem cells are CD34 + /CD45 dim /SSC low /FSClow to intermediate Neutrophils Bone NK cells T cells Basophils
The number of nucleated cells reflects the hematopoietic content of umbilical cord blood for transplantation
Bone Marrow Transplantation, (1999) 24, 965 970 1999 Stockton Press All rights reserved 0268 3369/99 $15.00 http://www.stockton-press.co.uk/bmt The number of nucleated cells reflects the hematopoietic
CHAPTER 3 LABORATORY PROCEDURES
CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES 3.1 HLA TYPING Molecular HLA typing will be performed for all donor cord blood units and patients in the three reference laboratories identified
BMTCN REVIEW COURSE PRE-TRANSPLANT CARE
BMTCN REVIEW COURSE PRE-TRANSPLANT CARE Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to edit the Master Experts
Leukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)
C Arbona, F Prosper, I Benet, F Mena, C Solano and J Garcia-Conde. Summary:
Bone Marrow Transplantation, (1998) 22, 39 45 1998 Stockton Press All rights reserved 0268 3369/98 $12.00 http://www.stockton-press.co.uk/bmt Comparison between once a day vs twice a day G-CSF for mobilization
The Role of Depletion of Dimethyl Sulfoxide before Autografting: On Hematologic Recovery, Side Effects, and Toxicity
Biology of Blood and Marrow Transplantation 10:135-141 (2004) 2004 American Society for Blood and Marrow Transplantation 1083-8791/04/1002-0006$30.00/0 doi:10.1016/j.bbmt.2003.09.016 The Role of Depletion
CryoStor CS2, CS5 and CS10 FREEZE MEDIA
CryoStor CS2, CS5 and CS10 FREEZE MEDIA Pre-Formulated Serum-Free Protein-Free cgmp Manufactured FDA Master File Sterility, Endotoxin, and Cell-Based Release Testing CryoStor, a series of cell-specific,
Leukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.08 Subject: Leukine Page: 1 of 5 Last Review Date: September 15, 2017 Leukine Description Leukine
Hematopoietic Stem Cells
Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, M irector, Hemotherapy and Stem Cell Processing Facility E-mail: js2745@columbia.edu Hematopoietic Stem Cells Sustain hematopoiesis
The Texas Medical Center
ISCT Regional Meeting November 2 4, 2007 Cryopreservation - Evaluation of Different Processes Presenters: Carlos Lee & Renee Smilee The Texas Medical Center Center for Cell & Gene Therapy The Feigin Center
& 2005 Nature Publishing Group All rights reserved /05 $
(25), 183 188 & 25 Nature Publishing Group All rights reserved 28-39/5 $ www.nature.com/bmt Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic
Cyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells
Bone Marrow Transplantation, (1999) 24, 959 963 1999 Stockton Press All rights reserved 0268 3369/99 $15.00 http://www.stockton-press.co.uk/bmt Cyclophosphamide and paclitaxel as initial or salvage regimen
What the Transfusion Scientist should know about Stem Cells. Dr Claire Wiggins BBTS September 2017
What the Transfusion Scientist should know about Stem Cells Dr Claire Wiggins BBTS September 2017 What is a stem cell? Undifferentiated cell Can divide and self renew for long periods Differentiate into
Sequential High-Dose Treatment with Peripheral Blood Progenitor Cell Transplantation in Patients with Multiple Myeloma
Sequential High-Dose Treatment with Peripheral Blood Progenitor Cell Transplantation in Patients with Multiple Myeloma Hartmut Goldschmidt, Ute Hegenbart, Marion Moos, Rita Eugenhart, Michael Wannenmacher;.
Human Induced Plutipotent Stem Cell (ipsc) Handling Protocols: Matrigel and mtesr/e8 Media
General Guidelines for Handling Human ipsc cells ipsc are cryopreserved in plastic cryovials and shipped on dry ice. If storing the ipsc before thawing, store in liquid nitrogen vapor. Storage directly
Predictive factors for long-term engraftment of autologous blood stem cells
(2000) 26, 1299 1304 2000 Macmillan Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nature.com/bmt Predictive factors for long-term engraftment of autologous blood stem cells PR Duggan 1, D
What can we learn from cryopreserved blood cells?
What can we learn from cryopreserved blood cells? Andreas Sputtek Universitätsklinikum Hamburg-Eppendorf Inst. f. Transfusionsmedizin Hamburg, Germany http://www.sputtek.de Plenary Lecture (Definition)
Citation for published version (APA): Hovenga, S. (2007). Clinical and biological aspects of Multiple Myeloma s.n.
University of Groningen Clinical and biological aspects of Multiple Myeloma Hovenga, Sjoerd IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation
Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, M irector, Hemotherapy and Stem Cell Processing Facility Bone Marrow Can Cure: Leukemia Lymphoma Multiple Myeloma Genetic iseases:
& 2003 Nature Publishing Group All rights reserved /03 $
(2003) 31, 263 267 & 2003 Nature Publishing Group All rights reserved 0268-3369/03 $25.00 www.nature.com/bmt Progenitor cell mobilization : safety profile and variables affecting peripheral blood progenitor
UMBILICAL CORD BLOOD STEM CELLS EXPANDED IN THE PRESENCE OF NICOTINAMIDE (NICORD) PROVIDE LONG TERM MULITI-LINEAGE ENGRAFTMENT
UMBILICAL CORD BLOOD STEM CELLS EXPANDED IN THE PRESENCE OF NICOTINAMIDE (NICORD) PROVIDE LONG TERM MULITI-LINEAGE ENGRAFTMENT Mitchell E. Horwitz, MD Duke University Medical Center Duke Cancer Institute
Introduction to Hematopoietic Stem Cell Transplantation
Faculty Disclosures Introduction to Hematopoietic Stem Cell Transplantation Nothing to disclose Jeanne McCarthy-Kaiser, PharmD, BCOP Clinical Pharmacist, Autologous Stem Cell Transplant/Long- Term Follow-Up
Back to the Future: The Resurgence of Bone Marrow??
Back to the Future: The Resurgence of Bone Marrow?? Thomas Spitzer, MD Director. Bone Marrow Transplant Program Massachusetts General Hospital Professor of Medicine, Harvard Medical School Bone Marrow
For research or further manufacturing use only. Not for injection or diagnostic procedures.
PRIME-XV T cell Expansion XSFM PRIME-XV T Cell Expansion XSFM is a xeno-free, serum-free medium optimized for the activation and expansion of human T lymphocytes. This medium contains gentamicin and requires
Duchez P, Chevaleyre J, Dazey B, Vlaski M, Ivanovic Z.
EX-VIVO EXPANSION OF CORD BLOOD HEMATOPOIETIC STEM AND PROGENITOR CELLS FOR TRANSPLANTATION USING AN ANTIOXYDANT-SUPPLIED MEDIUM AND A CYTOKINE COCKTAIL INDUCING HYPOXIC-LIKE CELLULAR RESPONSE Duchez P,
& 2003 Nature Publishing Group All rights reserved /03 $
(2003) 31, 823 828 & 2003 Nature Publishing Group All rights reserved 0268-3369/03 $25.00 www.nature.com/bmt Technical Report Preclinical evaluation of an automated closed fluid management device: Cytomate
TRANSPARENCY COMMITTEE. The legally binding text is the original French version OPINION. 21 June 2006
TRANSPARENCY COMMITTEE The legally binding text is the original French version OPINION 21 June 2006 Granocyte 13 (13.4 million IU/1 ml), powder and solvent in prefilled syringe for solution for injection
Clinical Policy: Donor Lymphocyte Infusion
Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte
What s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
Aldehyde dehydrogenase activity as a marker for the quality of hematopoietic stem cell transplants
(25) 35, 99 914 & 25 Nature Publishing Group All rights reserved 268-3369/5 $3. www.nature.com/bmt Aldehyde dehydrogenase activity as a marker for the quality of hematopoietic stem cell transplants MV
High-dose chemotherapy, followed by autologous
TRANSPLANTATION AND CELLULAR ENGINEERING A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma_02350 100..119
WAA/SFH Joint Congress
WAA/SFH Joint Congress Paris, 27 29 April 2016 Mobilization of HSC: History, evolution & impact Pitié-Sâlpétrière Hospital-Paris- France University Hospital of Paris-VI Nabih AZAR MD Key areas covered
Experimental Hematology 28 (2000) Service d Hématologie de l Hôpital Edouard Herriot, Lyon, France; b
Experimental Hematology 28 (2000) 858 870 Transplantation with selected autologous peripheral blood hematopoietic stem cells (HSCs) in multiple myeloma: Impact of HSC dose on engraftment, safety, and immune
Corporate Medical Policy
White Blood Cell Growth Factors Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: white_blood_cell_growth_factors 9/2016 4/2017 4/2018 6/2017 Description of
Neutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt
Neutrophil Recovery: The First Step in Posttransplant Recovery No conflicts of interest to disclose Bus11_1.ppt Blood is Made in the Bone Marrow Blood Stem Cell Pre-B White cells B Lymphocyte T Lymphocyte
Cord Blood Stem Cell Banking and Transplantation
Cord Blood Stem Cell Banking and Transplantation JOHN W. ADAMSON New York Blood Center, New York, New York, USA Key Words. Cord blood Stem cells Cord blood banking Cord blood transplantation. Cord blood.stern
"Chemotherapy based stem cell mobilization: pro and con"
"Chemotherapy based stem cell mobilization: pro and con" Mohamad MOHTY Clinical Hematology and Cellular Therapy Dpt. Sorbonne Université Hôpital Saint Antoine Paris, France Disclosures Sponsorship or research
Craig T. Wallington-Beddoe, 1,4 David J. Gottlieb, 1,2,4 Fran Garvin, 2 Vicki Antonenas, 2 Mary M. Sartor 3
Failure to Achieve a Threshold Dose of CD34 1 CD110 1 Progenitor Cells in the Graft Predicts Delayed Platelet Engraftment after Autologous Stem Cell Transplantation for Multiple Myeloma Craig T. Wallington-Beddoe,
Sponsor: Sanofi Drug substance(s): GZ316455
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
CXCR4 inhibitor plerixafor and G-CSF allow for an effective peripheral blood stem cell collection in patients who failed previous mobilization attempt
CXCR4 inhibitor plerixafor and G-CSF allow for an effective peripheral blood stem cell collection in patients who failed previous mobilization attempt Grzegorz Wladyslaw Basak 1 *, Elzbieta Urbanowska
New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
Cord Blood Bankers are. Angie Yost, MT(ASCP) CM 2016 ASCLS-MO CLMA Spring Meeting
Cord Blood Bankers are Angie Yost, MT(ASCP) CM 2016 ASCLS-MO CLMA Spring Meeting Objectives Cord blood 101 Manufacturing and cryopreservation Characterization testing Why Do We Need Cord Blood? Each year,
TRANSLATIONAL AND CLINICAL RESEARCH
TRANSLATIONAL AND CLINICAL RESEARCH Long-Term Follow-Up of Patients with Non-Hodgkin Lymphoma Following Myeloablative Therapy and Autologous Transplantation of CD34 -Selected Peripheral Blood Progenitor
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Sargramostim (Leukine) Reference Number: CP.PHAR.295 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important
3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)
3 Results 3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) Five infusions of monoclonal IL-2 receptor antibody (anti-cd25) were planned according to protocol between day 0 and day
90 min 18 min. 45 min. 14 d
Isolation, cultivation, and expansion of Pan T cells from human PBMCs In vitro expansion of human Pan T cells Introduction T lymphocytes (T cells) play a central role in the adaptive immune system by controlling
Automated and Standardized Counting of Mouse Bone Marrow CFU Assays
Automated and Standardized Counting of Mouse Bone Marrow CFU Assays 2 Automated and Standardized Colony Counting Table of Contents 4 Colony-Forming Unit (CFU) Assays for Mouse Bone Marrow 5 Automated Assay
EML Erythroid and Neutrophil Differentiation Protocols Cristina Pina 1*, Cristina Fugazza 2 and Tariq Enver 3
EML Erythroid and Neutrophil Differentiation Protocols Cristina Pina 1*, Cristina Fugazza 2 and Tariq Enver 3 1 Department of Haematology, University of Cambridge, Cambridge, UK; 2 Dipartimento de Biotecnologie
NINDS Repository Human Induced Pluripotent Stem Cell (ipsc) Handling Protocols (Matrigel and mtesr Media)
General Guidelines for Handling Human ipsc cells ipsc are cryopreserved in plastic cryovials and shipped on dry ice. If storing the ipsc before thawing, store in liquid nitrogen vapor. Storage directly
Aldehyde Dehydrogenase Activity as a Marker of Quality in Cryopreserved Cord Blood
Showa Univ J Med Sci 25 4, 297 306, December 2013 Original Aldehyde Dehydrogenase Activity as a Marker of Quality in Cryopreserved Cord Blood Hirokazu IKEDA, Daisuke TOYAMA, Ryosuke MATSUNO, Yoko FUJIMOTO
Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation
() 25, 723 728 Macmillan Publishers Ltd All rights reserved 268 3369/ $15. www.nature.com/bmt Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal
Human CD4+T Cell Care Manual
Human CD4+T Cell Care Manual INSTRUCTION MANUAL ZBM0067.04 SHIPPING CONDITIONS Human CD4+T Cells, cryopreserved Cryopreserved human CD4+T cells are shipped on dry ice and should be stored in liquid nitrogen
91154 PRIME-XV T Cell CDM Liquid 1 L Additional package sizes are available at request
PRIME-XV T CELL CDM PRIME-XV T Cell CDM is a ready-to-use chemically-defined, animal component-free medium. It is optimized and designed for the culture of T cells of human origin and recommended for use
Understanding the role of ex vivo T cell depletion
Prevention of graftversus-host disease (GVHD) Understanding the role of ex vivo T cell depletion Information for patients undergoing allogeneic stem cell transplantation in AML and their families 2 This
& 2007 Nature Publishing Group All rights reserved /07 $
() 9, & Nature Publishing Group All rights reserved 8-9/ $. www.nature.com/bmt ORIGINAL ARTICLE The impact of post-thaw colony-forming units-granulocyte/macrophage on engraftment following unrelated cord
Leukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.08 Subject: Leukine Page: 1 of 6 Last Review Date: March 13, 2014 Leukine Description Leukine (sargramostim)
Bone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
Hematopoietic stem cell mobilization and collection. Koen Theunissen Hematologie Jessa Ziekenhuis Hasselt Limburgs Oncologisch Centrum
Hematopoietic stem cell mobilization and collection Koen Theunissen Hematologie Jessa Ziekenhuis Hasselt Limburgs Oncologisch Centrum Transplants Transplant Activity in the U.S. 1980-2010 14,000 12,000
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
YOSHINORI KUDO, 1 MASAYOSHI MINEGISHI, 1 TSUNEO ITOH, 1 JUNKO MIURA, 1 NAOKO
Tohoku J. Exp. Med., 2005, 205, 37-43 Evaluation of Post-Thaw PBPC 37 Evaluation of Hematological Reconstitution Potential of Autologous Peripheral Blood Progenitor Cells Cryopreserved by a Simple Controlled-Rate
CELLULAR THERAPY QUIZ. Correct answers and rationale
CELLULAR THERAPY QUIZ Correct answers and rationale In January 2018, registered cellular therapy (CT) facilities were asked to participate in the quiz to determine the educational needs of the users regarding
Keywords: multiple myeloma; autologous; allogeneic stem cell transplantation. Summary:
Bone Marrow Transplantation, (1999) 23, 317 322 1999 Stockton Press All rights reserved 268 3369/99 $12. http://www.stockton-press.co.uk/bmt Induction therapy with vincristine, adriamycin, dexamethasone
Evaluation of Early Post-transplant Leukocyte Recovery Using the Undiluted Erythrocyte Lysing Technique
Annals of Clinical & Laboratory Science, vol. 32, no. 2, 2002 159 Evaluation of Early Post-transplant Leukocyte Recovery Using the Undiluted Erythrocyte Lysing Technique Myungshin Kim, 1 Ja Young Kim,
Granix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 7 Last Review Date: December 2, 2016 Granix Description Granix (tbo-filgrastim)
Allogeneic Stem Cell Transplantation with Peripheral Blood Stem Cells Mobilized by Pegylated G-CSF
Biology of Blood and Marrow Transplantation 12:63-67 (26) 26 American Society for Blood and Marrow Transplantation 183-8791/6/126-2$32./ doi:1.116/j.bbmt.26.3.1 Allogeneic Stem Cell Transplantation with
Human Umbilical Cord Blood CD34 + /133+ Progenitor Cell Care Manual
Human Umbilical Cord Blood CD34 + /133+ Progenitor Cell Care Manual INSTRUCTION MANUAL ZBM0065.04 SHIPPING CONDITIONS Human Umbilical Cord Blood CD34+/133+ Progenitor Cells, cryopreserved Cryopreserved
Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany;
Stem Cells Original Article Kinetics of Peripheral Blood Stem Cell Mobilization Following G-CSF-Supported Chemotherapy RUTH SEGGEWISS, a EIKE CHRISTIAN BUSS, a DORIS HERRMANN, b HARTMUT GOLDSCHMIDT, a
Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT
Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT Erin Meyer, DO, MPH Assistant Medical Director of Blood, Tissue, and Apheresis Services Children s Healthcare
Blood Components & Indications for Transfusion. Neda Kalhor
Blood Components & Indications for Transfusion Neda Kalhor Blood products Cellular Components: Red blood cells - Leukocyte-reduced RBCs - Washed RBCs - Irradiated RBCs Platelets - Random-donor platelets
Granix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Subject: Granix 1 of 7 Last Review Date: September 18, 2015 Granix Description Granix (tbo-filgrastim)
HSCT MANAGEMENT WHITE PAPER. Managing stem cell apheresis effectively
HAEMATOLOGY JANUARY 2017 WHITE PAPER HSCT MANAGEMENT Managing stem cell apheresis effectively Haematopoietic stem cell transplantation Haematopoietic stem cell transplantation (HSCT) is a treatment that
Ice recrystallization inhibition as a mechanism for reducing cryopreservation injury in a hematopoietic stem cell model
Ice recrystallization inhibition as a mechanism for reducing cryopreservation injury in a hematopoietic stem cell model Luke Wu This thesis is submitted as a partial fulfillment of the M.Sc. program in
For peripheral blood stem cell (PBSC) mobilization prior to and during leukapheresis in cancer patients preparing to undergo bone marrow ablation
Last Review: 4/2010 NON-FORMULARY Clinical Guideline Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF), Neumega (oprelvekin; rh-il-11), Leukine (sargramostim; GM-CSF) Indications Neupogen
US License Leukine (sargramostim) A Recombinant GM-CSF Yeast-Expressed. Rx only DESCRIPTION
US License 1752 Leukine (sargramostim) A Recombinant GM-CSF Yeast-Expressed Rx only DESCRIPTION LEUKINE (sargramostim) is a recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF)
The question is not whether or not to deplete T-cells, but how to deplete which T-cells
The question is not whether or not to deplete T-cells, but how to deplete which T-cells CD34+ positive selection Negative Depletion of: CD3/CD19 TcRαβ/CD19 T-cell depletion: positive selection versus negative
D Bonnet 1,2, M Bhatia 1,3, JCY Wang 1, U Kapp 1 and JE Dick 1. Summary:
Bone Marrow Transplantation, (1999) 23, 203209 1999 Stockton Press All rights reserved 02683369/99 $12.00 http://www.stockton-press.co.uk/bmt Cytokine treatment or accessory cells are required to initiate
Haploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks